INTRODUCTION
Monitoring treatment efficacy by non-imaging bedside methods is crucial in lung cancer, where The Response Evaluation Criteria in Solid Tumors (RECIST) assessment is performed every 2-3 cycles and sometimes even less frequently. A nonimaging method is particularly important when disease may respond to treatment, although the target lesions increase in size (pseudo-progression), as sometimes occurs with immunotherapies. Therefore, understanding treatment efficacy and its failure early in the course of therapy is extremely important and may improve treatment outcome [1] [2] [3] . To date, imaging has been primarily used in the assessment of response to anti-cancer treatment in lung cancer patients, Computerized Tomography (CT) being the mainstay. The RECIST [1] [2] [3] [4] approach categorizes the total response into one of 4 groups: complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD; see 'Methods') [4] . However, time-intervals between consecutive CT scans might be too long to allow early identification of treatment failure; moreover, scans are expensive and not always available.
An emerging approach that shows great promise in monitoring lung cancer (LC) treatment is based on volatile organic compounds (VOCs) emitted in breath samples [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . These VOCs emanate from the membrane of the cancer cells and/or from its surrounding tissues to the blood stream as a result of inflammation and oxidative stress, being excreted by diffusion across the pulmonary alveolar membrane and exhaled through the breath [15] [16] [17] . The role of VOCs as markers in various lung diseases, including cancer, has already been evaluated. Analysis of exhaled breath has already successfully distinguished asthmatic patients from healthy individuals [18, 19] , delineated COPD [20, 21] , differentiated between patients with LC and healthy patients with non-cancerous lung nodules [5, 6, 11, 14, 16, [22] [23] [24] [25] [26] [27] , and between subtypes of lung cancer [28] . Broza et al [29] have shown that breath analysis can be used for short-term follow-up after LC-resection. However, changes in VOCs in LC patients throughout the course of their disease and under systemic anti-cancer therapy have yet to be studied.
This study investigated the possibility of breath VOC signature being a marker for treatment efficacy in advanced lung cancer patients. Exhaled breath analysis is a simple non-invasive method that could allow the oncologist to recognize disease status during the course of treatment. In this prospective study, consecutive breath samples were collected from patients receiving systemic therapy for advanced stage LC. The samples were categorized into different response groups by matching them to their evaluation from sequential CT scans of the response of tumors to treatment. Several comparisons were conducted to identify differences in VOC patterns between the response groups. Two separate breath-analysis methods were used for this purposegas chromatography with mass spectrometry (GC-MS) and chemical nano-arrays (NA-NOSE). While GC-MS allowed the identification and quantification of a wide variety of separate breath VOCs, the NA-NOSE provided a sensor-based discrimination between the groups without regard to the nature and composition of the breath VOCs. All patients were given a written and verbal explanation about the study prior to their enrollment, and had signed a written consent of participation form. Each patient was interviewed regarding personal data, smoking habits and relevant medical history.
PATIENTS AND METHODS

Patients
Clinical characteristics of the study population are summarized in Table 1 .
Breath collection
Exhaled alveolar breath samples were collected from patients in a controlled manner.
The first breath sample was taken from each patient prior to and close to the start of the first systemic therapy cycle. Repeat samples were collected prior to and adjacent to subsequent cycles, or during follow-up meetings with the attending physician.
Patients were asked to refrain from smoking, and withhold alcohol and food consumption for 2 h prior to breath sampling. Alveolar exhaled breath was collected in chemically inert Mylar bags (Eco Medics, Duernten, Switzerland) in a controlled way after a 1 min procedure of a lung washout procedure described elsewhere [10, 11, 23] .
Breath collection was a single-step process that did not require changing between the dead space and alveolar breath bags. The content of each bag was transferred immediately through an offline procedure to a coded Tenax® sorbent tube (SKC Inc., Eighty Four, PA). The tubes were stored at 4ºC in a clean environment and transported to the Laboratory for Nanomaterial-Based Devices (Technion, Israel) for analysis by both GC-MS and the sensors' nano-array. 
Methods
Chemical analysis of breath samples
GC-MS were used to identify the exact composition and seek specific informative breath VOCs [7, 71, 87] . Gas chromatography uses a helium stream that carries the sample through a long heated capillary column to separate molecules in the VOCs mixture according to their volatility, more volatile compounds travelling faster than less volatile ones. Due to the difference in the chemical properties in the mixture, each molecule has a different exit time from the column (the retention time). The mass spectrometer determines molecular mass and chemical structure of the VOCs after being broken up into characteristic fragments and ionized. In the mass analyzer, the ions are filtered by an electric field according to their mass/charge (m/z) ratio. The retention time and the mass charge ratio are used to identify the compounds by a spectral library in the GC software, thus reducing the possibility of error in identification. The first breath sample of each patient was taken as the Baseline Sample (BL).
Subsequent samples were matched with the next proximal CT scan of the patient, and categorized according to one of the 4 abovementioned groups. Analysis included only breath samples that met one or more of the following criteria: (1) a breath sample that was taken up to 3 months prior to the last available CT scan; (2) a breath sample that was taken up to 3 weeks after the last available CT scan. If more than one CT scan was available that fulfilled the criteria, the sample was categorized by the latest scan. 
(iii) PD samples
The clinical status of each event was defined relative to the previous disease status.
Statistical analysis
The breath samples were analyzed using 2 independent approaches in 2 phases. In 
RESULTS:
A summary of the clinical data of each of the advanced LC patients who participated are given in Table 1 . Approximately 80% were males, mean age 62 ± 7.2 years.
Former smokers accounted for 69% (average 52 ± 24 pack years); 18% were current smokers (average 86 ± 54 pack years), and 13% had never been smokers ( Table 1) .
Most (85%) of the patients had Non-Small Cell Lung Cancer (NSCLC) with different histological diagnoses (squamous cell, adenocarcinoma and "not otherwise specified" (NOS)). Only 15% of the patients had Small Cell Lung Cancer (SCLC). (Table 1) BL numbered 39 samples, while there were 47 samples in the PR group, 38 in the SD group, and 11 in the PD group ( Table 2) .
Chemical analysis of the breath samples
In the first phase, we identified VOCs that could be useful as biomarkers in monitoring the response of a cancer to treatment. By GC-MS analysis, ~200 relevant VOCs were identified, all with main masses in the range of 33 to 282 m/z and retention times between 1.6 and 39.8 min. Seventeen of these VOCs were found in >90% of the samples, with a similarity index >85%. Using these 17 VOCs, binary comparisons were conducted, as given above in detail under 'Methods', and summarized in show any significant discriminant VOCs between PR and SD cases.
Nano-array analysis of the breath samples:
In the second phase of the study, 131 breath samples were exposed to nano-array sensors, of which 4 samples were excluded for technical reasons. Thirty-eight were BL samples, 48 were PR, 34 were SD, and 11 were PD.
We examined whether the sensor array could estimate and monitor tumor responsiveness to treatment, thereby alerting us about possible changes in tumor behavior. For this purpose, we developed 2 predictive models based on breath samples collected from 38 patients using DFA. Twenty-seven patients presented SD or PR at the first assessment, in whom the first DFA model attempted to identify disease control (DC samples) after the first treatment compared with the BL. This model showed a sensitivity of 93%, a specificity of 85% and an accuracy of 89% after leave-one-out cross-validation. The Positive Predicted Value (PPV) and Negative Predicted Value (NPV) for identification of DC were 86 and 92%, respectively.
In the second DFA model, we distinguished 83 samples categorized as DC from 11 samples categorized as PD. Despite achieving 100% specificity and 92% classification accuracy, the sensitivity was only 28%, whereas the PPV and NPV for identification of PD were 100 and 91%, respectively. Because of too few numbers of samples, we did not analyze patients who had PD in the first few cycles.
Our main challenge was to monitor the single patient and be alerted to any change in the response to therapy, which could be achieved by using HBC-3 sensor. This study indicates that exhaled-breath analysis may serve as a simple, user-friendly method of monitoring response to systemic therapy in lung cancer. Its particular importance is its potential to recognize failure very early on in the course of therapy before it becomes manifest by routine imaging schedules. This may help the physician to make better, more up-to-date, rational decisions regarding the cancer treatment selected for each patient. Likewise, in cases in remission (e.g. case #17 in Table 8 and Figure 5 ), exhaled breath may serve as a surrogate marker of disease recurrence.
Most importantly, both methodologies could recognize disease control within the first assessment, which is particularly important as it might avoid inefficient therapy that might have significant adverse effects.
Conceptually, consecutive breath-samples would be collected from a patient at fixed times after receiving a cycle of anti-cancer treatment before initiating another cycle of therapy. Because of its simplicity, breath-collection can be done the physician's office.
By using the signals received from the sensor-array, the physician could create a patient's personal 'hot-plot'(as in Figure 2 ). Its scale allows the physician to assess the patient's response to treatment and take appropriate clinical action.
In this study, 2 powerful tools were used: (i) GC-MS. which is effective in the identification and quantification of human volatolomics. 
Use of volatile biomarkers for monitoring response to treatment
The source of the exhaled VOCs is not well understood [40] . We identified 3 VOCs as markers for response (Table 3) 
Use of sensor-array for evaluation of treatment response
The sensor-array analysis provides an easier and more intuitive indication. Analysis achieved a relatively high accuracy in the 2 sets of classifications. The first DFA model (see 'Methods') took into consideration patients who had reached disease control after the initial treatment (i.e. SD or PR). Their baseline samples compared with their subsequent samples showed a relatively high classification capability (93% sensitivity and 85% specificity). The second DFA model compared PR/SD samples with subsequent PD status; the specificity (true negative value) in this model was 100%, but the sensitivity was only 28%, indicating that it is highly reliable in detecting negative progression of the disease and lack of response to treatment (PD states).
In practice, these results indicate that the physician can predict a positive response to treatment starting from the first session with a PPV of 86%. Following initial assessment, the physician can use sensor set 2 to test whether the patient had a positive response (PR/SD) or did not respond to treatment, i.e. the disease had progressed (PD). In this case, the PPV was 100%, implying that identification of a sample as PD is 100% trustworthy. These are only preliminary results that require a larger study group for validation; nevertheless, the results support the potential use of the NA-NOSE as a monitoring tool and show its ability to discriminate between response and lack of response to anti-cancer treatment.
The attempt to use only one sensor in monitoring the response to treatment led to an interesting pattern presented as a hot-plot in Figure 2 , which displays each patient separately. Each sample is normalized to the previous sample from the same patient, and is colored according to the resistance of the sensor for the specific sample. If one assumes correct identification in achieving Disease Control (SD+PR) vs. lack of response to treatment (PD), 85% percent of the cases were identified and colored correctly by the single sensor (HBC-3). There may be several explanations regarding the cases that were wrongly identified. First, some cases could have been categorized wrongly, mainly because sometimes the true volume or progression of the cancer is not well represented in the CT scans -either the changes might still be too small to trace, or a new tumor focus exists in a part of the body that was not scanned and therefore was not recognized. In such cases, samples categorized as PR/SD might actually be PD. In the same way, a sample categorized as SD might actually be PR if a positive response to treatment has been detected by the sensor, but not as yet by the CT scan. A second possibility is that, in this hot-plot, each sample is normalized to the previous one; but in some cases, the time-interval between the 2 samples has been too long (due to clinical reasons, e.g. prolonged lack of evidence of disease), and normalization then gives an inaccurate result.
Future potential and clinical applications
GC-MS has many disadvantages such as being time-consuming, costly, requiring cumbersome equipment and specialized knowledge in order to analyze the results.
Therefore, the nano-array method is a more realistic option for use in clinical practice in the future, requiring only compact and easy to use equipment, and does not require pre-concentration and/or dehumidification procedures. The sensors are broadly crossreactive, respond to a wide range of compounds, and are less affected by noise than the detected (sub) ppb-ppm concentrations of the compounds identified by the GC-MS. Moreover, the sensors can be tuned to show very low sensitivity to confounding
VOCs from the surroundings, whereas the GC-MS detects these confounding VOCs, thereby introducing noise into the measurement of the compounds of interest, which is likely to affect the overall accuracy of the method [5, 6, 16, 29] .
The limitations of this study include a relatively small cohort group. However, we had a total of 143 comparisons and an internal longitudinal monitoring was also used for all the patients, with a longest period of 14 months. We enrolled patients under range of treatments, including chemotherapies and targeted therapies. We assume that tumor death produces most of the volatile signature, breath sampling being done 3
weeks from the most recent cycle, i.e. away from the direct effect of the drug.
Focusing on subgroup analysis, we managed to distinguish SCLC from NSCLC with 100% sensitivity and 94% specificity (95% accuracy); adenocarcinoma from squamous cell with 75% sensitivity and 95% specificity (92% accuracy); mutation vs.
non-mutation with 90% sensitivity and 50% specificity (81% accuracy). These are interesting and valid results; however, they do not reflect the need of sub-division of the results in assessing the use of breath sampling in monitoring response to anticancer treatment. Due to small sample size, we unfortunately were unable to draw a surrogate model for every subgroup.
In summary, standardization of assessment in tumor responsiveness is important in allowing effective comparisons between results of different cancer treatments. As strongly rooted in the clinical 'language', we expect RECIST to remain the primary criteria for the assessment of response to treatment in cancer patients, with advanced and novel monitoring techniques being used as adjuncts. This study offers a proof-ofconcept of the idea that exhaled breath can provide a new modality in monitoring the response to anti-cancer treatment in patients with advanced lung cancer. It can help to define disease progression during conventional chemotherapy, molecular targeted therapy, or both. Monitoring tumor response to treatment during shorter intervals than currently available by CT scans should allow earlier decision-making regarding the chosen treatment. We believe that future research of exhaled breath analysis will yield excellent results that pave the way to using VOCs as markers for cancer diseases and for monitoring disease progression. Ideally, further studies require a larger study group and closer follow-up, which will give a more precise categorization of breath samples and statistically stronger results.
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